Is Corcept Therapeutics (CORT) Stock a Buy after Renee Gala’s Insider Purchase?; Teleflex (TFX) Had 8 Analysts Last Week

Among 11 analysts covering Teleflex (NYSE:TFX), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Teleflex had 34 analyst reports since July 31, 2015 according to SRatingsIntel. On Tuesday, January 30 the stock rating was maintained by Leerink Swann with “Buy”. Morgan Stanley maintained the stock with “Equal-Weight” rating in Friday, November 3 report. The stock of Teleflex Incorporated (NYSE:TFX) earned “Buy” rating by Morgan Stanley on Wednesday, September 6. The firm earned “Buy” rating on Tuesday, March 7 by Needham. As per Tuesday, June 14, the company rating was maintained by Barclays Capital. The stock of Teleflex Incorporated (NYSE:TFX) has “Overweight” rating given on Monday, November 30 by Piper Jaffray. The firm earned “Buy” rating on Friday, February 26 by Brean Capital. The firm has “Buy” rating given on Monday, June 26 by Barclays Capital. The stock has “Buy” rating by Jefferies on Thursday, February 22. The stock has “Buy” rating by Piper Jaffray on Friday, November 10. See Teleflex Incorporated (NYSE:TFX) latest ratings:

22/02/2018 Broker: Jefferies Rating: Buy New Target: $290.0 Maintain
23/02/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $321 New Target: $300 Maintain
30/01/2018 Broker: Leerink Swann Rating: Buy New Target: $321.0 Maintain
17/01/2018 Broker: Stephens Rating: Buy New Target: $300.0 Maintain
18/12/2017 Broker: Raymond James Rating: Buy New Target: $300.0
16/11/2017 Broker: KeyBanc Capital Markets Rating: Hold Maintain
14/11/2017 Broker: Deutsche Bank Old Rating: Buy New Rating: Hold Downgrade
10/11/2017 Broker: Piper Jaffray Rating: Buy New Target: $295.0 Initiate
03/11/2017 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $274 New Target: $290 Maintain
03/11/2017 Broker: Needham Rating: Buy New Target: $285.0 Maintain

Renee Gala, the well informed person, who’s presently the director of Corcept Therapeutics Inc made a purchase of roughly 10,000 shares of the company with a total value of about $155,102 U.S Dollars based on an average weighted cost of 15.5 U.S Dollars for a share. Today, Renee Gala owns 10,000 shares which are around 0.01% of Corcept Therapeutics Inc’s market capitalization.

Investors sentiment increased to 1.13 in Q3 2017. Its up 0.03, from 1.1 in 2017Q2. It is positive, as 23 investors sold Teleflex Incorporated shares while 114 reduced holdings. 49 funds opened positions while 102 raised stakes. 39.29 million shares or 3.24% less from 40.61 million shares in 2017Q2 were reported. Skyline Asset Mgmt L P reported 1.14% stake. Leavell Management Incorporated holds 0.13% or 4,500 shares in its portfolio. Dimensional Fund Advsr Lp stated it has 0.03% in Teleflex Incorporated (NYSE:TFX). Moreover, Eulav Asset has 0.04% invested in Teleflex Incorporated (NYSE:TFX). Moreover, Winslow Evans Crocker has 0.01% invested in Teleflex Incorporated (NYSE:TFX). 28,216 were accumulated by Oregon Pub Employees Retirement Fund. Gateway Inv Advisers Ltd Liability Com stated it has 0.04% of its portfolio in Teleflex Incorporated (NYSE:TFX). Parnassus Invs Ca holds 0.38% or 380,000 shares. Oak Ridge Invests owns 16,406 shares or 0.16% of their US portfolio. Bahl & Gaynor holds 0.14% or 53,108 shares in its portfolio. Envestnet Asset Management Inc invested in 4,436 shares. Dekabank Deutsche Girozentrale owns 3,396 shares. British Columbia Inv Mngmt holds 0.03% or 14,508 shares in its portfolio. Point72 Asia (Hong Kong) Limited invested in 400 shares or 0.07% of the stock. Citigroup Inc invested 0% of its portfolio in Teleflex Incorporated (NYSE:TFX).

The stock increased 1.31% or $3.33 during the last trading session, reaching $257.65. About 376,406 shares traded or 22.71% up from the average. Teleflex Incorporated (NYSE:TFX) has risen 24.36% since March 8, 2017 and is uptrending. It has outperformed by 7.66% the S&P500.

Since October 2, 2017, it had 0 insider purchases, and 8 insider sales for $3.14 million activity. $707,775 worth of Teleflex Incorporated (NYSE:TFX) was sold by BABICH GEORGE JR. $55,288 worth of Teleflex Incorporated (NYSE:TFX) was sold by Klasko Stephen K. M.D.. Deren John sold $347,449 worth of Teleflex Incorporated (NYSE:TFX) on Tuesday, February 27.

Teleflex Incorporated designs, develops, makes, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company has market cap of $11.61 billion. It offers vascular access products consisting of Arrow branded catheters and related devices for critical care therapies, including the administration of intravenous medications and other therapies, the measurement of blood pressure, and withdrawal of blood samples; interventional access products that are used in dialysis, oncology, and critical care therapies; and anesthesia products, such as airway management products under the LMA and Rusch brands, and pain management products under the Arrow brand. It has a 78.77 P/E ratio. The firm also provides surgical products, such as ligating clips and fascial closure systems; bladeless access ports, sutures, and other surgical instruments; and single-use and reusable products for surgical procedures under the Deknatel, Pilling, Kmedic, Hem-o-lok, and Weck brands.

Investors sentiment decreased to 1.49 in Q3 2017. Its down 0.47, from 1.96 in 2017Q2. It fall, as 13 investors sold Corcept Therapeutics Incorporated shares while 39 reduced holdings. 47 funds opened positions while 55 raised stakes. 71.96 million shares or 6.38% more from 67.64 million shares in 2017Q2 were reported. Nationwide Fund owns 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 50,615 shares. Jasper Ridge Partners Limited Partnership owns 10,000 shares or 0.01% of their US portfolio. Morgan Stanley holds 373,585 shares. Manufacturers Life Ins The owns 179,974 shares for 0% of their portfolio. Art Advsrs Lc holds 0.13% or 129,914 shares. First Tru Ltd Partnership reported 205,812 shares. Prudential Financial Inc stated it has 0.04% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT). 10,397 were accumulated by Tower Research Capital Ltd Limited Liability Company (Trc). Schwab Charles Investment Mngmt has invested 0.01% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT). Ameritas Invest Prns reported 8,001 shares. 5,800 were accumulated by Pacad Investment Ltd. James Inv Research reported 117,400 shares. Macquarie Gru Ltd, a Australia-based fund reported 7,100 shares. Clarivest Asset Mgmt Ltd Liability Company has 0.03% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 67,921 shares. Tudor Inv Corporation Et Al owns 0.02% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 34,734 shares.

Since December 8, 2017, it had 0 buys, and 3 sales for $415,899 activity. FISHMAN ROBERT S sold $132,774 worth of Corcept Therapeutics Incorporated (NASDAQ:CORT) on Wednesday, February 7.

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company has market cap of $1.81 billion. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It has a 15.16 P/E ratio. The firm is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer.

The stock increased 2.14% or $0.33 during the last trading session, reaching $15.77. About 1.12 million shares traded. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 124.81% since March 8, 2017 and is uptrending. It has outperformed by 108.11% the S&P500.

Among 4 analysts covering Corcept Therapeutics (NASDAQ:CORT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corcept Therapeutics has $25.0 highest and $14 lowest target. $20.75’s average target is 31.58% above currents $15.77 stock price. Corcept Therapeutics had 7 analyst reports since February 2, 2017 according to SRatingsIntel. Piper Jaffray maintained it with “Buy” rating and $24.0 target in Wednesday, October 11 report. Ladenburg Thalmann initiated it with “Buy” rating and $14 target in Thursday, February 2 report. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) earned “Buy” rating by Piper Jaffray on Friday, September 8. Piper Jaffray maintained Corcept Therapeutics Incorporated (NASDAQ:CORT) on Thursday, August 24 with “Buy” rating. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) earned “Buy” rating by Stifel Nicolaus on Friday, November 3.